



**SZABO  
SCANDIC**

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](http://linkedin.com/company/szaboscandic)



# ThrRS (h3): 293T Lysate: sc-170842

## BACKGROUND

Aminoacyl-tRNA synthetases function to catalyze the aminoacylation of tRNAs by their corresponding amino acids, thus linking amino acids with tRNA-contained nucleotide triplets. ThrRS (threonyl-tRNA synthetase), also known as TARS, is a 723 amino acid member of the class-II aminoacyl-tRNA synthetase family that catalyzes the tRNA(Thr)-threonine aminoacylation reaction. Localized to the cytoplasm, ThrRS contains a zinc-binding catalytic domain, a C terminal tRNA-binding domain and an N terminal editing domain. ThrRS has four mobile regions, three of which have a key residue that changes conformation throughout catalysis, thereby mediating the dynamics of the tRNA-amino acid reaction. The fourth mobile region contains an ordering loop which helps to close the active site once the substrate (threonine) is in place.

## REFERENCES

1. Sankaranarayanan, R., Dock-Bregeon, A.C., Romby, P., Caillet, J., Springer, M., Rees, B., Ehresmann, C., Ehresmann, B. and Moras, D. 1999. The structure of threonyl-tRNA synthetase-tRNA(Thr) complex enlightens its repressor activity and reveals an essential zinc ion in the active site. *Cell* 97: 371-381.
2. Torres-Larios, A., Sankaranarayanan, R., Rees, B., Dock-Bregeon, A.C. and Moras, D. 2003. Conformational movements and cooperativity upon amino acid, ATP and tRNA binding in threonyl-tRNA synthetase. *J. Mol. Biol.* 331: 201-211.
3. Ishikura, H., Nagaoka, Y., Yokozawa, J., Umehara, T., Kuno, A. and Hasegawa, T. 2003. Threonyl-tRNA synthetase of archaea: importance of the discriminator base in the aminoacylation of threonine tRNA. *Nucleic Acids Symp. Ser.* 83-84.
4. Ruan, B., Bovee, M.L., Sacher, M., Stathopoulos, C., Poralla, K., Francklyn, C.S. and Söll, D. 2004. A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. *J. Biol. Chem.* 280: 571-577.
5. Yamasaki, Y., Yamada, H., Nozaki, T., Akaogi, J., Nichols, C., Lyons, R., Loy, A.C., Chan, E.K., Reeves, W.H. and Satoh, M. 2006. Unusually high frequency of autoantibodies to PL7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. *Arthritis Rheum.* 54: 2004-2009.
6. Hussain, T., Kruparani, S.P., Pal, B., Dock-Bregeon, A.C., Dwivedi, S., Shekar, M.R., Sureshbabu, K. and Sankaranarayanan, R. 2006. Posttransfer editing mechanism of a D-aminoacyl-tRNA deacylase-like domain in threonyl-tRNA synthetase from archaea. *EMBO J.* 25: 4152-4162.
7. Asanuma, Y., Koichihara, R., Koyama, S., Kawabata, Y., Kobayashi, S., Mimori, T. and Moriguchi, M. 2006. Antisynthetase syndrome associated with sarcoidosis. *Intern. Med.* 45: 1065-1068.
8. Ling, J., Roy, H. and Ibba, M. 2007. Mechanism of tRNA-dependent editing in translational quality control. *Proc. Natl. Acad. Sci. USA* 104: 72-77.
9. Kim, C.W., Han, K.S., Ryu, K.S., Kim, B.H., Kim, K.H., Choi, S.I. and Seong, B.L. 2007. N-terminal domains of native multidomain proteins have the potential to assist *de novo* folding of their downstream domains *in vivo* by acting as solubility enhancers. *Protein Sci.* 16: 635-643.

## CHROMOSOMAL LOCATION

Genetic locus: TARS (human) mapping to 5p13.3.

## PRODUCT

ThrRS (h3): 293T Lysate represents a lysate of human ThrRS transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

## APPLICATIONS

ThrRS (h3): 293T Lysate is suitable as a Western Blotting positive control for human reactive ThrRS antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

## STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.